{
    "code": "52026291",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026291",
    "time": "2020-06-26 06:04:35",
    "許可證字號": "衛部藥輸字第026291號",
    "註銷狀態": "已註銷",
    "註銷日期": "109\/04\/08",
    "註銷理由": "屆期未申請展延",
    "製造許可登錄編號": "",
    "有效日期": "108\/03\/24",
    "發證日期": "103\/03\/24",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202629100",
    "中文品名": "&quot;卡比&quot;癌通定凍晶注射劑",
    "英文品名": "TOPOTEL Injection 4mg\/Vial (Lyophilized)",
    "適應症": "卵巢癌及小細胞肺癌之第二線化學治療(第一線化療應包括白金化合物)topotecan與cisplatin併用適用於治療經組織學檢查確定患有第IV-B期復發性或持續性子宮頸癌，且不適合以外科手術及(或)放射療法進行治療的患者。",
    "劑型": "243凍晶注射劑",
    "包裝": "4毫克玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "TOPOTECAN HYDROCHLORIDE",
    "限制項目": "02輸　入 24監視期滿學名藥",
    "申請商名稱": "6201179728  台灣費森尤斯卡比股份有限公司",
    "申請商地址": "台北市大安區仁愛路三段30號5樓32號5樓",
    "主製造廠": [
        {
            "製造廠名稱": "FIN0368000  FRESENIUS KABI ONCOLOGY LIMITED",
            "製造廠廠址": "VILLAGE-KISHANPURA, P.O. GURU MAJRA, TEHSIL-NALAGARH, DISTT. SOLAN, (H.P.)-174101, INDIA",
            "製造廠公司地址": "",
            "製造廠國別": "INDIA",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000310",
            "成分名稱": "TOPOTECAN HYDROCHLORIDE",
            "含量描述": "(equivalent to Topotecan)",
            "含量": "4.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "癌通定凍晶注射劑_仿單-103-07-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026291&Seq=001&Type=9"
        },
        {
            "title": "癌通定凍晶注射劑_外紙盒及瓶標-103-07-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026291&Seq=002&Type=8"
        }
    ]
}